Related Experiment Videos
Hepatitis B immunization in low birthweight infants: do they need an additional dose?
N K Arora1, S Ganguly, S N Agadi
1Department of Pediatrics, All India Institute of Medical Sciences, New Delhi. nkmanan@hotmail.com
Acta Paediatrica (Oslo, Norway : 1992)
|November 5, 2002
Summary
Preterm infants benefit from an additional hepatitis B vaccine dose for protective anti-HB levels, while term intrauterine growth-retarded infants should follow standard schedules. This strategy aims to prevent vertical transmission and enhance immune response in preterm infants.
Area of Science:
- Immunology
- Pediatrics
- Vaccinology
Background:
- Hepatitis B virus (HBV) infection poses a significant risk, especially in endemic areas.
- Assessing the immune response to HBV vaccination in preterm (PT) and term intrauterine growth-retarded (T-IUGR) infants is crucial for effective prevention strategies.
- Understanding the impact of gestational age and birth weight on vaccine efficacy is essential for optimizing infant immunization schedules.
Purpose of the Study:
- To evaluate the influence of gestation and birth weight on protective anti-hepatitis B (anti-HB) antibody levels after three doses of HBV vaccine.
- To determine the necessity of a fourth HBV vaccine dose for low birthweight infants.
- To compare the immune response between PT and T-IUGR infants.
Main Methods:
- A study involving 82 PT and 60 T-IUGR infants who received the Enivac HB vaccine at birth and at 6, 10, and 14 weeks of life.
- Measurement of protective anti-HB levels (>10 mIU/ml) after the third and fourth vaccine doses.
- Analysis of the association between gestational age, birth weight, maternal anti-HB antibodies, and vaccine response.
Main Results:
- Protective anti-HB levels were achieved in 86.6% of PT infants and 96.7% of T-IUGR infants after three doses.
- Increased gestation was associated with a higher likelihood of a protective response (odds ratio 1.25 per week increase).
- A fourth vaccine dose significantly increased protective antibody levels in PT infants, particularly those without maternal antibodies, but offered no benefit to T-IUGR infants.
Conclusions:
- Preterm infants, regardless of birth weight, may benefit from an additional HBV vaccine dose in a schedule starting at birth to prevent vertical transmission and match term infant immune responses.
- Term intrauterine growth-retarded infants should adhere to the standard vaccination schedule for normal term infants.
- Further research with different vaccine formulations and longer follow-up is needed to widely implement this strategy.